Decreased biosynthesis of lung surfactant constituent phosphatidylcholine due to inhibition of choline transporter by gefitinib in lung alveolar cells

Pharmaceutical Research

Volumn 25, Issue 2, 2008, Pages 417-427

  Ishiguro, Naoki ^a   Oyabu, Masanobu ^a   Sato, Toshihiro ^a   Maeda, Tomoji ^a   Minami, Hironobu ^b   Tamai, Ikumi ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Alveolar type II; Choline; Gefitinib; Lung toxicity; Phosphatidylcholine

Indexed keywords

CARRIER PROTEIN; CHOLINE; CHOLINE TRANSPORTER; CHOLINE TRANSPORTER LIKE PROTEIN 1; GEFITINIB; HEMICHOLINIUM 3; LUNG SURFACTANT; MESSENGER RNA; ORGANIC CATION TRANSPORTER 3; PHOSPHATIDYLCHOLINE; PROTEIN; SODIUM; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; CELL ACTIVITY; CELL LINE; CHOLINE UPTAKE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG ALVEOLUS CELL; LUNG ALVEOLUS CELL TYPE 2; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; CELLS, CULTURED; CHOLINE; HUMANS; ORGANIC CATION TRANSPORT PROTEINS; PHOSPHATIDYLCHOLINES; PULMONARY ALVEOLI; PULMONARY SURFACTANTS; QUINAZOLINES; RATS; RATS, WISTAR;

EID: 39149135866     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9362-9     Document Type: Article

References (39)

1. S. H. Landis, T. Murray, S. Bolden, and P. A. Wingo. Cancer statistics, 1999. CA Cancer J. Clin. 49:8-31, 1 (1999).
2. A. Inoue, Y. Saijo, M. Maemondo, K. Gomi, Y. Tokue, Y. Kimura, M. Ebina, T. Kikuchi, T. Moriya, and T. Nukiwa. Severe acute interstitial pneumonia and gefitinib. Lancet 361:137-139 (2003).
3. I. Okamoto, K. Fujii, M. Matsumoto, Y. Terasaki, N. Kihara, H. Kohrogi, and M. Suga. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 40:339-42 (2003).
4. N. Thatcher, A. Chang, P. Parikh, J. Rodrigues Pereira, T. Ciuleanu, J. von Pawel, S. Thongprasert, E. H. Tan, K. Pemberton, V. Archer, and K. Carroll. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537 (2005).
5. K. Aoe, A. Hiraki, T. Murakami, T. Maeda, Y. Umemori, H. Katayama, R. Eda, and H. Takeyama. Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy. Anticancer Res. 25:415-418 (2005).
6. N. N. Jarjourand and G. Enhorning. Antigen-induced airway inflammation in atopic subjects generates dysfunction of pulmonary surfactant. Am. J. Respir. Crit. Care Med. 160:336-341 (1999).
7. A. H. Jobeand and M. Ikegami. Surfactant and acute lung injury. Proc. Assoc. Am. Physicians 110:489-495 (1998).
8. P. R. Lockmanand and D. D. Allen. The transport of choline. Drug Dev. Ind. Pharm. 28:749-771 (2002).
9. D. H. Sweet, D. S. Miller, and J. B. Pritchard. Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus. J. Biol. Chem. 276:41611-41619 (2001).
10. T. Okuda, T. Haga, Y. Kanai, H. Endou, T. Ishihara, and I. Katsura. Identification and characterization of the high-affinity choline transporter. Nat. Neurosci. 3:120-125 (2000).
11. H. Misawa, K. Nakata, J. Matsuura, M. Nagao, T. Okuda, and T. Haga. Distribution of the high-affinity choline transporter in the central nervous system of the rat. Neuroscience 105:87-98 (2001).
12. S. O'Regan and F. M. Meunier. Selection and characterization of the choline transport mutation suppressor from Torpedo electric lobe, CTL1. Neurochem. Res. 28:551-555 (2003).
13. S. O'Regan, E. Traiffort, M. Ruat, N. Cha, D. Compaore, and F. M. Meunier. An electric lobe suppressor for a yeast choline transport mutation belongs to a new family of transporter-like proteins. Proc. Natl. Acad. Sci. USA 97:1835-1840 (2000).
14. M. Lieber, B. Smith, A. Szakal, W. Nelson-Rees, and G. Todaro. A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int. J. Cancer. 17:62-70 (1976).
15. K. Miquel, A. Pradines, F. Terce, S. Selmi, and G. Favre. Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. J. Biol. Chem. 273:26179-26186 (1998).
16. L. G. Dobbs, R. Gonzalez, and M. C. Williams. An improved method for isolating type II cells in high yield and purity. Am. Rev. Respir. Dis. 134:141-145 (1986).
17. Y. Kikkawa and K. Yoneda. The type II epithelial cell of the lung. I. Method of isolation. Lab. Invest. 30:76-84 (1974).
18. E. G. Bligh and W. J. Dyer. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37:911-917 (1959).
19. M. H. Cohen, G. A. Williams, R. Sridhara, G. Chen, W. D. McGuinn, Jr., D. Morse, S. Abraham, A. Rahman, C. Liang, R. Lostritto, A. Baird, and R. Pazdur. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 10:1212-1218 (2004).
20. G. Yamano, H. Funahashi, O. Kawanami, L. X. Zhao, N. Ban, Y. Uchida, T. Morohoshi, J. Ogawa, S. Shioda, and N. Inagaki. ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells. FEBS Lett. 508:221-225. (2001).
21. N. Cheong, M. Madesh, L. W. Gonzales, M. Zhao, K. Yu, P. L. Ballard, and H. Shuman. Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome. J. Biol. Chem. 281:9791-9800, Epub 2006 Jan 16. (2006).
22. J. E. Bullard, S. E. Wert, and L. M. Nogee. ABCA3 deficiency: neonatal respiratory failure and interstitial lung disease. Semin. Perinatol. 30:327-334. (2006).
23. N. Ban, Y. Matsumura, H. Sakai, Y. Takanezawa, M. Sasaki, H. Arai, and N. Inagaki. ABCA3 as a Lipid Transporter in Pulmonary Surfactant Biogenesis. J. Biol. Chem. 282:9628-9634, Epub 2007 Jan 30. (2007).
24. R. Schmidt, U. Meier, P. Markart, F. Grimminger, H. G. Velcovsky, H. Morr, W. Seeger, and A. Gunther. Altered fatty acid composition of lung surfactant phospholipids in interstitial lung disease. Am. J. Physiol. Lung. Cell. Mol. Physiol. 283:L1079-L1085 (2002).
25. D. McKillop, M. Hutchison, E. A. Partridge, N. Bushby, C. M. Cooper, J. A. Clarkson-Jones, W. Herron, and H. C. Swaisland. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 34:917-934 (2004).
26. S. Apparsundaram, S. M. Ferguson, A. L. George, Jr., and R. D. Blakely. Molecular cloning of a human, hemicholinium-3-sensitive choline transporter. Biochem. Biophys. Res. Commun. 276:862-867 (2000).
27. M. D. Fullerton, L. Wagner, Z. Yuan, and M. Bakovic. Impaired trafficking of choline transporter like protein-1 at the plasma membrane and inhibition of choline transport in THP-1 monocyte-derived macrophages. Am. J. Physiol. Cell Physiol. (2005).
28. V. Gorboulev, J. C. Ulzheimer, A. Akhoundova, I. Ulzheimer-Teuber, U. Karbach, S. Quester, C. Baumann, F. Lang, A. E. Busch, and H. Koepsell. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 16:871-881 (1997).
29. G. D. van Rossumand and C. A. Boyd. Sodium-dependent and -independent choline uptake by type II epithelial cells from rat lung. J. Membr. Biol. 162:147-156 (1998).
30. K. C. Stone, R. R. Mercer, P. Gehr, B. Stockstill, and J. D. Crapo. Allometric relationships of cell numbers and size in the mammalian lung. Am. J. Respir. Cell Mol. Biol. 6:235-243 (1992).
31. J. Baselga, D. Rischin, M. Ranson, H. Calvert, E. Raymond, D. G. Kieback, S. B. Kaye, L. Gianni, A. Harris, T. Bjork, S. D. Averbuch, A. Feyereislova, H. Swaisland, F. Rojo, and J. Albanell. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20:4292-4302 (2002).
32. R. S. Herbst, A. M. Maddox, M. L. Rothenberg, E. J. Small, E. H. Rubin, J. Baselga, F. Rojo, W. K. Hong, H. Swaisland, S. D. Averbuch, J. Ochs, and P. M. LoRusso. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 20:3815-3825 (2002).
33. K. Nakagawa, T. Tamura, S. Negoro, S. Kudoh, N. Yamamoto, K. Takeda, H. Swaisland, I. Nakatani, M. Hirose, R. P. Dong, and M. Fukuoka. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann. Oncol. 14:922-930 (2003).
34. M. Ranson, L. A. Hammond, D. Ferry, M. Kris, A. Tullo, P. I. Murray, V. Miller, S. Averbuch, J. Ochs, C. Morris, A. Feyereislova, H. Swaisland, and E. K. Rowinsky. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 20:2240-2250 (2002).
35. H. C. Swaisland, M. Ranson, R. P. Smith, J. Leadbetter, A. Laight, D. McKillop, and M. J. Wild. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin. Pharmacokinet. 44:1067-1081 (2005).
36. M. Hayer-Zillgen, M. Bruss, and H. Bonisch. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br. J. Pharmacol. 136:829-836 (2002).
37. J. Alcorn, X. Lu, J. A. Moscow, and P. J. McNamara. Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction. J. Pharmacol. Exp. Ther. 303:487-496 (2002).
38. D. Kristufek, W. Rudorfer, C. Pifl, and S. Huck. Organic cation transporter mRNA and function in the rat superior cervical ganglion. J. Physiol. 543:117-134 (2002).
39. M. Inazu, H. Takeda, and T. Matsumiya. Molecular and functional characterization of an Na+-independent choline transporter in rat astrocytes. J. Neurochem. 94:1427-1437 (2005).